1/21/2013

The Drug Controller General of India, which regulates the country's pharmaceuticals, has asked drugmakers to conduct clinical trials of all generic drugs and seek approval within 18 months. The move is in response to abuse of legal loopholes that enabled some companies to bypass DGCI and sell drugs with dangerous side effects, many of which are banned abroad.

Full Story:
BioSpectrum Asia

Related Summaries